First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 studyArjun Vasant Balar, Joaquim Bellmunt, Daniel Castellano et al.|The Lancet Oncology|2017Cited by 1.3k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial CarcinomaThomas Powles, Noah M. Hahn, Jae‐Lyun Lee et al.|JAMA Oncology|2017Cited by 846
Assessment of time-to-treatment-failure (TTF) as a surrogate endpoint for overall survival (OS) to immune checkpoint inhibitor (ICI) regimens in metastatic renal cell carcinoma (mRCC): Findings from an IMDC analysis.Zachary A. Yochum, Toni K. Choueiri, Renée Maria Saliby et al.|Journal of Clinical Oncology|2025Cited by 0